Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer

European Urology

Volumn 69, Issue 6, 2016, Pages 992-995

  Cheng, Heather H ^a,b   Pritchard, Colin C ^c   Boyd, Thomas ^d   Nelson, Peter S ^b   Montgomery, Bruce ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d North Star Lodge Cancer Center   (United States)

Author keywords

BRCA2; Carboplatin; DNA repair; mCRPC; Platinum; Prostate cancer

Indexed keywords

ABIRATERONE; BRCA2 PROTEIN; CARBOPLATIN; DOCETAXEL; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; DOXORUBICIN; TAXOID;

ADULT; AGED; ALLELE; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CASTRATION RESISTANT PROSTATE CANCER; COPY NUMBER VARIATION; DISEASE COURSE; DNA REPAIR; DNA SEQUENCE; DRUG SENSITIVITY; ENZYME INACTIVATION; FRAMESHIFT MUTATION; GERMLINE MUTATION; GLEASON SCORE; HUMAN; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MIDDLE AGED; NEXT GENERATION SEQUENCING; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; SOMATIC MUTATION; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; GENETICS; MUTATION; PATHOLOGY; SECONDARY; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; AGED; ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; DOXORUBICIN; GENES, BRCA2; HUMANS; MALE; MIDDLE AGED; MUTATION; PROSTATECTOMY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS;

EID: 84951794612     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.11.022     Document Type: Article

References (10)

1. E. Basch, D.A. Loblaw, T.K. Oliver, and et al. Systemic therapy in men with metastatic castration-resistant prostate cancer. American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline J Clin Oncol 32 2014 3436 3448
2. C.S. Grasso, Y.M. Wu, D.R. Robinson, and et al. The mutational landscape of lethal castration-resistant prostate cancer Nature 487 2012 239 243
3. H. Beltran, R. Yelensky, G.M. Frampton, and et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity Eur Urol 63 2013 920 926
4. D. Robinson, E.M. Van Allen, Y.M. Wu, and et al. Integrative clinical genomics of advanced prostate cancer Cell 161 2015 1215 1228
5. H. Beltran, S. Tomlins, A. Aparicio, and et al. Aggressive variants of castration-resistant prostate cancer Clin Cancer Res 20 2014 2846 2850
6. D.S. Tan, C. Rothermundt, K. Thomas, and et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations J Clin Oncol 26 2008 5530 5536
7. E. Castro, C. Goh, D. Leongamornlert, and et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer Eur Urol 68 2015 186 193
8. C.L. Scott, E.M. Swisher, and S.H. Kaufmann Poly (ADP-ribose) polymerase inhibitors: recent advances and future development J Clin Oncol 33 2015 1397 1406
9. J. Mateo, S. Carreira, S. Sandhu, and et al. DNA-repair defects and olaparib in metastatic prostate cancer N Engl J Med 373 2015 1697 1708
10. C.C. Pritchard, S.J. Salipante, K. Koehler, and et al. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens J Mol Diagn 16 2014 56 67